Core Viewpoint - The company, along with its wholly-owned subsidiary Sichuan Yiyigou Technology Group Co., Ltd., has established a new entity, Sichuan Jindoudou Smart Technology Co., Ltd., with a registered capital of 50 million yuan to enhance its non-pharmaceutical health product business [1] Group 1 - The company holds 100% equity in Jindoudou Smart Technology through direct and indirect shareholding [1] - The new subsidiary has completed its business registration and obtained a business license from the Chengdu Jin Niu District Government Service Management and Administrative Approval Bureau [1] - The company aims to leverage its established flow channels in the outpatient pharmaceutical distribution service to expand into the non-pharmaceutical health product sector, positioning itself as a leading player in the health technology ecosystem [1] Group 2 - The newly established subsidiary will focus on the operation of non-pharmaceutical health products and will develop a specialized system for product selection, procurement, warehousing, and distribution [1] - The company plans to build data-driven service capabilities to create a competitive ecosystem in the non-pharmaceutical industry [1]

证券代码：300937 证券简称：药易购 公告编号：2025-038 四川合纵药易购医药股份有限公司 关于设立全资子公司暨取得营业执照的 四川合纵药易购医药股份有限公司（以下简称"公司"）及全资子公司四川 药易购科技集团有限公司（以下简称"药易购科技集团"）共同投资设立四川金 豆豆数智科技有限公司（以下简称"金豆豆数智科技"），注册资本 5,000 万元， 资金来源为公司及药易购科技集团自有资金。公司通过直接持股以及下属子公司 间接持股合计持有金豆豆数智科技 100%股权，金豆豆数智科技已于近日完成工 商注册登记，并取得成都市金牛区政务服务管理和行政审批局颁发的《营业执照》。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等有关规定， 本次投资设立全资子公司事项无需提交董事会、股东会审议。本次投资设立全资 子公司事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定 的重大资产重组。 二、设立全资子公司的基本情况 公司名称：四川金豆豆数智科技有限公司 统一社会信用代码：91510106MAEQPHM09W 公司类型： ...

目前，公司董事长为林志辉，董秘为施艺雄，员工人数为2839人，实际控制人为漳州市人民政府国有资产监督管理委员会。 雷达财经 文|冯秀语 编|李亦辉 8月6日，片仔癀(600436)公告，公司全资子公司漳州片仔癀投资管理有限公司拟作为有限合伙人以自有或自筹资金认缴出资人民币20,000万元，参与投资漳 州高鑫润信大健康产业投资合伙企业（有限合伙）（暂定名）。该基金目标募集规模为人民币10亿元，主要投资于医疗健康领域。本次投资构成关联交易， 已通过公司内部审议流程，但基金仍处于筹备设立阶段。 天眼查资料显示，片仔癀成立于1999年12月28日，注册资本60331.721万人民币，法定代表人林志辉，注册地址为福建省漳州市芗城区琥珀路1号。主营业务 为医药制造业、医药流通业及化妆品业等。 公司参股公司55家，包括福建片仔癀电子商务有限公司、漳州片仔癀投资管理有限公司、福建片仔癀健康科技有限公司、片仔癀电商国际贸易（香港）有限 公司、漳州片仔癀国药堂医药连锁有限公司等。 在业绩方面，公司2022年至2024年营业收入分别为86.94亿元、100.58亿元和107.88亿元，同比分别增长8.38%、15.69%和7.25 ...

Core Viewpoint - The company Pianzaihuang (600436) announced an investment of 200 million yuan in a health industry investment partnership, aiming to enhance its strategic development and core competitiveness in the medical sector [1] Investment Details - The investment will be made by the company's wholly-owned subsidiary, Zhangzhou Pianzaihuang Investment Management Co., Ltd., using self-owned or raised funds [1] - The target fundraising scale of the partnership is 1 billion yuan, with the company’s investment accounting for 20% of this amount [1] - The fund will primarily invest in the healthcare sector, including pharmaceuticals, medical devices, and health-related supply chains, with non-healthcare investments capped at 10% [1] Strategic Objectives - The investment aims to leverage professional institutional resources to accelerate the concentration of the pharmaceutical industry, strengthen industry chain integration, and enhance core competitiveness [1] - The fund is managed by CITIC Jinshi Capital, which has extensive experience and expertise in the healthcare sector [1] Related Transactions - This investment is conducted in conjunction with related parties, including Zhangzhou Pianzaihuang Asset Management Co., Ltd. and Zhangzhou Tourism Investment Group Co., Ltd., and is classified as a related party transaction without constituting a major asset restructuring [1] Company Performance - In the first quarter of 2025, the company achieved a total operating revenue of 3.142 billion yuan and a net profit attributable to the parent company of 1 billion yuan [1]

近年来，华润医药商业经营规模位居行业前列，营收和净利润有所增长，但毛利率有下降趋势。 根据2025年6月披露的"25润药05"公司债(第三期)募集说明书，2022—2024年度，华润医药商业实现营 业收入分别为1,828.87亿元、2,024.81亿元和2,132.00亿元；其中，公司医疗纯销业务收入分别为1,271.12 亿元、1,426.67亿元和1,481.96亿元，分别占营业收入的69.50%、70.46%和69.51%，为公司最主要的营 业收入来源。 财报数据显示，2022—2024年度，华润医药商业净利润分别为17.85亿元、19.68亿元及22.13亿元；同期 营业毛利率分别为6.88%、6.47%及6.51%。 据华润医药商业官网资料，这家总资产超过1500亿元的医药流通企业前身为北京医药股份有限公司， 2010年进入华润体系，由地区性公司发展成为全国性医药流通企业。2012年，公司更名为华润医药商业 集团有限公司，此后于2023混改引战成功，进入股权多元化新时期。 此次公司高层人事调整，由现任华润医药商业党委副书记、总经理郭霆代行财务负责人职责，公司公告 称将尽快安排聘任新任财务负责人。与此 ...

● 优先股代码：360047 ● 优先股简称：九州优 ● 优先股面值：100元/股 ● 每股优先股派发现金股息：人民币5.00元（含税） ● 最后交易日：2025年8月8日（星期五） ● 股权登记日：2025年8月11日（星期一） ● 除息日：2025年8月11日（星期一） ● 股息发放日：2025年8月12日（星期二） 一、优先股股息派发审议情况 1、计息期间：2024年8月12日至2025年8月11日； 2、最后交易日：2025年8月8日（星期五）； 3、股权登记日：2025年8月11日（星期一）； 4、除息日：2025年8月11日（星期一）； 5、股息发放日：2025年8月12日（星期二）； 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 重要内容提示： 九州通医药集团股份有限公司（以下简称"公司"）2022年第二次临时股东大会审议通过了《关于公司非 公开发行优先股方案的议案》，授权董事会在股东会审议通过的框架和原则下，依照发行文件的约定， 宣派和支付全部优先股股息。2025年6月17日，公司召开第六届董事会第十五次会议， ...

Core Viewpoint - 九州通医药集团股份有限公司 announced the implementation of the preferred stock dividend distribution plan, with a cash dividend of RMB 5.00 per share (including tax) based on a 5.00% coupon rate [1][4]. Summary by Sections Preferred Stock Dividend Distribution Review - The company’s second extraordinary general meeting in 2022 approved the non-public issuance of preferred shares and authorized the board to declare and pay all preferred stock dividends according to the issuance documents [1]. - The board meeting on June 17, 2025, approved the preferred stock dividend distribution plan [1]. Preferred Stock Dividend Distribution Plan - The interest calculation period starts from the payment deadline of the preferred stock issuance, with annual payment dates on the anniversary of the payment deadline [1]. - The dividend will be distributed on August 12, 2025, with the interest period from August 12, 2024, to August 11, 2025 [1]. Dividend Distribution Details - The dividend distribution is for 17.9 million shares, totaling RMB 89,500,000 (including tax) at a rate of RMB 5.00 per share [4]. - Tax obligations for cash dividends will be borne by the shareholders according to relevant regulations [4]. Important Dates - Last trading day: August 8, 2025 [2][3] - Record date: August 11, 2025 [2][3] - Ex-dividend date: August 11, 2025 [2][3] - Dividend payment date: August 12, 2025 [2][3].

证券代码：600998 证券简称：九州通 公告编号：临 2025-058 九州通医药集团股份有限公司 优先股 2025 年股息派发实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 九州通医药集团股份有限公司（以下简称"公司"）2022 年第二次临时股东 大会审议通过了《关于公司非公开发行优先股方案的议案》，授权董事会在股东 会审议通过的框架和原则下，依照发行文件的约定，宣派和支付全部优先股股息。 ，同意按照 5.00%的票面股息率（票面面值为 100 司优先股股息派发方案的议案》 ，向优先股股东派发股息每股 5.00 元（含税） 元/股） （详见公司公告：临 2025-047）。 二、优先股股息派发方案 根据公司披露的《九州通向特定对象发行优先股募集说明书》约定，计息起 始日为公司本次优先股发行的缴款截止日，每年的付息日为本次优先股发行的缴 款截止日起每满一年的当日，如该日为法定节假日或休息日，则顺延至下一个工 作日。九州优将于 2025 年 8 月 12 日实施本次股息发放，具体实施日期如下： 登记结算 ...

Core Insights - Guofa Co., Ltd. (600538) has announced the appointment of a special auditing firm for a simplified procedure to issue A-shares to specific investors, with a total financing amount not exceeding 300 million yuan [1] - The company is focused on the health sector, covering pharmaceutical manufacturing, distribution, and IVD (in vitro diagnostics) [1] - A new diversified executive team has been established, including Chairman Jiang Ye and President Zhang Xiaowei, to drive the company's new development strategy [1] Company Developments - The IVD industry is transitioning from "single testing" to "precision and full-cycle management," with companies having core technological breakthroughs and global integration advantages becoming more competitive [1] - Guofa's subsidiary, Gao Sheng Bio, has developed an ultra-micro DNA automatic extraction workstation, enhancing automation in sample preparation and achieving success in forensic DNA second-generation sequencing library construction [1] - The company plans to focus on brand marketing for its eye drop product "Haibao" this year, which is recognized as a key technological innovation project and included in the national medical insurance and essential drug list [2] Strategic Initiatives - In late July, Chairman Jiang Ye led a visit to DaoKe Technology, a leading cloud-native operating system company, signaling the company's exploration into the AI field [2]

Group 1: Industry Overview - The Chinese pharmaceutical distribution market can be divided into three competitive tiers, with the first tier consisting of national wholesale giants such as China National Pharmaceutical Group, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong, all generating over 100 billion in revenue [1] - The retail pharmacy rankings show Dazhenlin at the top, followed by Guoyao Pharmacy and Yifeng Pharmacy, indicating significant changes in the top five rankings compared to the previous year [3] - The e-commerce segment is led by Ark Health's online pharmacy, which is pioneering a new H2H (Hospital To Home) smart healthcare model [4] Group 2: Strategic Analysis - The strategic cluster analysis of listed companies in the pharmaceutical distribution industry indicates that leaders such as China Resources Pharmaceutical, Shanghai Pharmaceuticals, Jiuzhoutong, and China National Pharmaceutical Group have revenues exceeding 100 billion and are well-established in the market [5] - The competitive landscape is characterized by intense competition, with numerous participants including wholesale and retail pharmaceutical companies, as well as brand operators entering the supply chain [7] Group 3: Competitive Forces - The analysis using Porter's Five Forces model reveals a highly competitive environment in the pharmaceutical distribution industry, with a quantification of competitive forces ranging from 0 (minimum) to 1 (maximum) [7]